03 / June / 2026 Daraxonrasib: the story of a drug that took 44 years to develop A New York Times report chronicles four decades of research culminating in the development of daraxonrasib, a drug that doubled the overall survival of patients with metastatic pancreatic cancer By Diogo Rodriguez
